Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Citigroup Inc. (C) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Citigroup Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.54 (market cap $29.60B), while Citigroup Inc. trades at $137.63 (market cap $227.75B). The key difference: Citigroup Inc. is far larger — about 7.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Citigroup Inc. pays a 1.97% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | C | |
|---|---|---|
Market Cap | $29.60B | $227.75B |
Sector | Health | Financials |
52-Week High | $491.22 | $145.67 |
52-Week Low | $205.48 | $92.59 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Citigroup (C) trades at $137.78, up 1.89% today, with a bullish technical signal from moving averages and a consensus analyst price target of $154.38. Recent Q2 2026 earnings beat expectations with EPS of $3.15 versus $2.72 expected, while revenue reached a decade high. The company is actively hiring senior bankers and launching digital trade solutions, signaling strategic growth initiatives.
The outlook is positive, supported by earnings momentum and a 59% analyst buy rating, but risks include volatile cash flows from operations and high leverage. The stock offers potential upside to the price target, with investor focus on execution of the medium-term ROTCE target of 14-15%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →
